BESIVANCE
BAUSCH LOMB INCORPORATED
Identification
- Active ingredient (INN)
- BESIFLOXACINE
- Internal code
- 17 D 182
- Country of Origin
- United States
- Pharmaceutical form
- Ophthalmic Suspension
- Prescription List
- Highly Regulated (List I)
- Packaging
- b/01 flacon 5ml
DAWA Clinical Workbench v2.0
Information may not be accurate. Always consult a physician, pharmacist, or specialist before acting on any data shown here.
Description
Besifloxacin is a fourth generation fluoroquinolone-type opthalmic antibiotic for the treatment of bacterial conjunctivitis.
FDA approved on
May 28, 2009.
Indications
Treatment of bacterial conjunctivitis.
Bacterial isolates that are susceptible to besifloxacin include: CDC coryneform group G; Corynebacterium pseudodiphtheriticum; Corynebacterium striatum; Haemophilus influenzae; Moraxella lacunata; Staphylococcus aureus; Staphylococcus epidermidis; Staphylococcus hominis; Staphylococcus lugdunensis; Streptococcus mitis group; Streptococcus oralis; Streptococcus pneumoniae; Streptococcus salivarius*
Pharmacodynamics
Besifloxacin tear concentrations were higher than
MIC90 (minimum inhibitory concentration) values for common bacterial pathogens and sustained for 24 hours or longer.
Mean residence time in the conjunctiva was 4.7 hours.
Mechanism of Action
topoisomerase 4 subunit A (Haemophilus influenzae (strain ATCC 51907 / DSM 11121 / KW20 / Rd)) Antagonist DNA topoisomerase 4 subunit A (Streptococcus pneumoniae serotype 4 (strain ATCC BAA-334 / TIGR4)) Antagonist DNA gyrase subunit A (Haemophilus influenzae (strain ATCC 51907 / DSM 11121 / KW20 / Rd)) Antagonist + 1 more target.
Absorption
Although ocular surface concentrations are high, average systemic concentrtions after three-times daily dosing was less than 0.5 ng/mL.
This indicates that besifloxacin is not appreciably absorbed into the systemic and has a very low risk of systemic side effects.
Half-life
The average elimination half-life of besifloxacin in plasma following multiple dosing was estimated to be 7 hours.
Adverse Effects
Improve decision support & research outcomes With structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates.
View sample adverse effects data in our new Data Library! See the data Improve decision support & research outcomes with our structured adverse effects data.
Toxicity
LD50, rat: >2000 mg/kg. The most common adverse reaction reported in 2% of patients treated with besifloxacin was conjunctival redness.